1204918-72-8 | TG02 (Double bond E)

Packsize	Purity	Availability	Price	Discounted Price
1mg	98+%	in stock	$18.00	$13.00
5mg	98+%	in stock	$43.00	$30.00
10mg	98+%	in stock	$64.00	$45.00
25mg	98+%	in stock	$107.00	$75.00

Description

• Catalog Number: AE27522
• Chemical Name: TG02 (Double bond E)
• CAS Number: 1204918-72-8
• Molecular Formula: C23H24N4O
• Molecular Weight: 372.4629
• MDL Number: MFCD22124499
• SMILES: CN1C/C=C/CCOc2cccc(c2)c2[nH]/c(=N\c3cc(C1)ccc3)/ncc2

Computed Properties

• Complexity: 499
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 1
• XLogP3: 4.2

Literature

• Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).

  Journal of molecular modeling 20130101

• Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.

  BMC pharmacology & toxicology 20130101

• The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.

  British journal of haematology 20121001

• Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.

  Drug metabolism letters 20120301

• TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.

  Leukemia 20120201

• Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.

  Journal of medicinal chemistry 20120112